Recent announcements

Register online today at https://hub.pointbiopharma.com/investor-day-june-2023

PNT2004 program’s phase 1 FRONTIER trial design to be presented. Abstract to be released at 5:00 PM ET, May 25th. Poster to be available starting at 9:00 AM ET, June 3rd.

U.S. FDA granted Fast Track designation for 177Lu-PNT2002 for the treatment of mCRPC in April 2023. Announces $10 million strategic investment in commercial-scale alpha-emitting isotope manufacturer, Ionetix Alpha Corp.

POINT further strengthens supply chain with $10 million investment in Ionetix Alpha Corp.

“The FDA Fast Track designation for 177Lu-PNT2002 underscores its potential to address a serious unmet need and serve as a meaningful therapeutic option for patients with mCRPC,” said Dr. Neil Fleshner, M.D., Chief Medical Officer of POINT Biopharma.

Eckert & Ziegler will provide predetermined amounts of GMP grade Ac-225 to POINT for use in the development of POINT’s pipeline of next generation Ac-225-based radioligands.

Signed Strategic Collaboration Agreement with Lantheus Holdings Inc. for POINT's PNT2002 and PNT2003 product candidates. Completed enrollment for randomization phase of PNT2002's phase 3 SPLASH registrational trial, with top line data expected in the second half of 2023.

POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today affirmed that the SPLASH clinical trial for the PSMA-targeted PNT2002 program is not experiencing any manufacturing or drug supply issues or delays.